About
Science
Pipeline
Jobs
News
News
Read the latest from HI-Bio™
All
Press Releases
July 2, 2024
Biogen Completes Acquisition of Human Immunology Biosciences
Press Releases
May 25, 2024
HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients
Press Releases
May 24, 2024
HI-Bio Presents Positive Interim Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at 61st European Renal Association (ERA) Congress
Press Releases
May 22, 2024
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
Press Releases
March 29, 2024
HI-Bio to Present at the 61st European Renal Association (ERA) Congress
Press Releases
March 21, 2024
HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection (AMR) in Kidney Transplant Recipients
Press Releases
January 4, 2024
HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases
Press Releases
October 31, 2023
HI-Bio Announces Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration for Primary Membranous Nephropathy (PMN)
1
2
3